Spots Global Cancer Trial Database for nose cancer
Every month we try and update this database with for nose cancer cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
---|---|---|---|---|---|---|
Tabelecleucel in Combination With Pembrolizumab in Subjects With Epstein-Barr Virus-associated Nasopharyngeal Carcinoma (EBV+ NPC) | NCT03769467 | Nasopharyngeal ... Nasopharyngeal ... Epstein-Barr Vi... Epstein-Barr Vi... Epstein-Barr Vi... | tabelecleucel pembrolizumab | 12 Years - | Atara Biotherapeutics | |
A Clinical Study on Oncolytic Virus Injection (R130 OV) for the Treatment of Relapsed/Refractory Head and Neck Cancer | NCT05830240 | Head and Neck C... Esophageal Canc... Otorhinolaryngo... Ear Cancer Nose Cancer Laryngeal Cance... Pharyngeal Canc... | Recombinant onc... | 18 Years - 75 Years | Shanghai Yunying Medical Technology | |
A Phase III Trial Evaluating Chemotherapy and Immunotherapy for Advanced Nasopharyngeal Carcinoma (NPC) Patients | NCT02578641 | Nasopharyngeal ... | autologous EBV ... combination IV ... | 18 Years - | Tessa Therapeutics | |
Tabelecleucel in Combination With Pembrolizumab in Subjects With Epstein-Barr Virus-associated Nasopharyngeal Carcinoma (EBV+ NPC) | NCT03769467 | Nasopharyngeal ... Nasopharyngeal ... Epstein-Barr Vi... Epstein-Barr Vi... Epstein-Barr Vi... | tabelecleucel pembrolizumab | 12 Years - | Atara Biotherapeutics | |
A Clinical Study on Oncolytic Virus Injection (R130 OV) for the Treatment of Relapsed/Refractory Head and Neck Cancer | NCT05830240 | Head and Neck C... Esophageal Canc... Otorhinolaryngo... Ear Cancer Nose Cancer Laryngeal Cance... Pharyngeal Canc... | Recombinant onc... | 18 Years - 75 Years | Shanghai Yunying Medical Technology |